Adamas Pharmaceuticals, Inc. (ADMS) moved up $1.72, or 5.3%, on Tuesday, closing at $33.87 on very light volume of 606,000 shares traded. Collegium Pharmaceutical, Inc. (COLL) picked up 31 cents, closing at $18.49 on light volume of 337,800 shares traded Tuesday. The stock chart's On-Balance Volume indicator has held steady during the present bull wedge consolidation period, signaling that the stock has been accumulated during the past few months. Today the company announced closing of its agreement, initially announced last month, to license opioid Nucynta from Depomed, a move that Collegium's CEO said will help them achieve profitability faster. The company announced Monday that BeiGene will license the commercialization of Mirati's tumor drug in the Asia Pacific region.

Source: Forbes January 11, 2018 15:45 UTC